Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Emergency Use Authorization
Cue Health receives FDA emergency use authorization for molecular mpox test
The test demonstrated high accuracy in clinical trials, achieving 100% concordance with the Center for Disease Control and Prevention’s (CDC's) mpox test on the samples tested, Cue Health said.
March 20, 2023
Mologic receives FDA EUA for at-home SARS-CoV-2 antigen test, eyes additional respiratory diseases
The development of the rapid antigen test was funded under an $11.8 million contract through the US National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative.
February 27, 2023
Lucira Health files for bankruptcy despite receiving FDA green light
The firm is seeking a strategic or financial partner for the resumption of manufacturing and development of additional home diagnostic testing products.
February 27, 2023
FDA authorizes Lucira Health OTC test, the first to detect influenza and COVID-19 viruses
In people with symptoms, the Lucira COVID-19 & Flu Test correctly identified 99.3% of negative and 90.1% of positive influenza A samples; 100% of negative and 88.3% of positive COVID-19 samples; and 99.9% of negative influenza B samples, the FDA said.
February 24, 2023
FDA grants emergency use authorization for Anavasi LAMP-based COVID-19 test, detector
Anavasi said its point-of-care platform will enable the rapid development of tests to detect viral and bacterial targets, including influenza, respiratory syncytial virus (RSV), and sexual health-related strains, among others.
February 13, 2023
FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care
The Xpert Mpox test is a real-time polymerase chain reaction assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.
February 10, 2023
BD nabs FDA authorization for SARS-CoV-2, influenza A/B, RSV combination test
The test uses a single nasal or nasopharyngeal swab sample to identify and distinguish whether a patient has COVID-19, the flu, RSV, or some combination of the three, with results available in two hours.
February 8, 2023
LumiraDx obtains FDA authorization for test to detect flu A, flu B, SARS-CoV-2
The test leverages a single-step direct method for nucleic acid extraction and amplification on validated open RT-PCR instruments.
February 7, 2023
Lucira Health applies for FDA Emergency Use Authorization of over-the-counter COVID-19, flu A, flu B molecular test
The single-use test fits in the palm of the hand, runs on two AA batteries, and with one shallow nasal swab provides a positive or negative result for COVID-19, flu A, or flu B in less than 30 minutes.
January 3, 2023
Visby Medical receives FDA Emergency Use Authorization for respiratory test in CLIA-waived settings
The Respiratory Health Test is a rapid PCR device that detects and differentiates upper respiratory infections caused by influenza A & B and SARS-CoV-2.
January 3, 2023
CorDx receives FDA Emergency Use Authorization for COVID-19 antigen test
The COVID-19 Ag lateral flow immunoassay provides qualitative detection of the nucleocapsid protein antigen from the SARS-CoV-2 virus, providing a result in 10 minutes.
December 1, 2022
Roche obtains FDA authorization for monkeypox test on high-throughput MDx system
Roche's Cobas MPXV test targets two different regions of the MPXV genome which are both less prone to mutations than other parts of the genome, the firm said.
November 16, 2022
Page 1 of 14
Next Page
